Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Even now, with the dip in value, its price-to-earnings (P/E) multiple is close to 80, which still isn't terribly cheap ... Eli Lilly still has a couple of fantastic drugs in Mounjaro and Zepbound ...

Eli Lilly’s pipeline holds substantial promise, particularly with the FDA’s approval of Zepbound for Obstructive ... with a market cap of $793 billion. A discounted cash flow (DCF) analysis ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound ... it easier for patients to access its discount and savings schemes.

These super high-flying US stocks have soared 222%, 122%, and 150%, respectively, in 2025. Let's take a look why.